5 O
. O

WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Hepatotoxicity O
: O
Inform O
patients O
of O
warning O
signs O
and O
symptoms O
of O
hepatotoxicity O
. O

Discontinue O
if O
abnormal O
liver O
tests O
persist O
or O
worsen O
or O
if O
clinical O
signs O
and O
symptoms O
of O
liver O
disease O
develop O
( O
5.3 O
) O
* O
Hypertension O
: O
Patients O
taking O
some O
antihypertensive O
medications O
may O
have O
impaired O
response O
to O
these O
therapies O
when O
taking O
NSAIDs O
. O

Monitor O
blood O
pressure O
( O
5.4 O
, O
7 O
) O
* O
Heart O
Failure O
and O
Edema O
: O
Avoid O
use O
of O
CELEBREX O
in O
patients O
with O
severe O
heart O
failure O
unless O
benefits O
are O
expected O
to O
outweigh O
risk O
of O
worsening O
heart O
failure O
( O
5.5 O
) O
* O
Renal O
Toxicity O
: O
Monitor O
renal O
function O
in O
patients O
with O
renal O
or O
hepatic O
impairment O
, O
heart O
failure O
, O
dehydration O
, O
or O
hypovolemia O
. O

Avoid O
use O
of O
CELEBREX O
in O
patients O
with O
advanced O
renal O
disease O
unless O
benefits O
are O
expected O
to O
outweigh O
risk O
of O
worsening O
renal O
function O
( O
5.6 O
) O
* O
Anaphylactic O
Reactions O
: O
Seek O
emergency O
help O
if O
an O
anaphylactic O
reaction O
occurs O
( O
5.7 O
) O
* O
Exacerbation O
of O
Asthma O
Related O
to O
Aspirin O
Sensitivity O
: O
CELEBREX O
is O
contraindicated O
in O
patients O
with O
aspirin-sensitive O
asthma O
. O

Monitor O
patients O
with O
preexisting O
asthma O
( O
without O
aspirin O
sensitivity O
) O
( O
5.8 O
) O
* O
Serious O
Skin O
Reactions O
: O
Discontinue O
CELEBREX O
at O
first O
appearance O
of O
skin O
rash O
or O
other O
signs O
of O
hypersensitivity O
( O
5.9 O
) O
* O
Premature O
Closure O
of O
Fetal O
Ductus O
Arteriosus O
: O
Avoid O
use O
in O
pregnant O
women O
starting O
at O
30 O
weeks O
of O
gestation O
( O
5.10 O
, O
8.1 O
) O
* O
Hematologic O
Toxicity O
: O
Monitor O
hemoglobin O
or O
hematocrit O
in O
patients O
with O
any O
signs O
or O
symptoms O
of O
anemia O
( O
5.11 O
, O
7 O
) O
5.1 O
Cardiovascular O
Thrombotic O
Events O
Clinical O
trials O
of O
several O
COX-2 O
selective O
and O
nonselective O
NSAIDs O
of O
up O
to O
three O
years O
duration O
have O
shown O
an O
increased O
risk O
of O
serious O
cardiovascular B-OSE_Labeled_AE
( I-OSE_Labeled_AE
CV I-OSE_Labeled_AE
) I-OSE_Labeled_AE
thrombotic I-OSE_Labeled_AE
events I-OSE_Labeled_AE
, O
including O
myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
( I-OSE_Labeled_AE
MI I-OSE_Labeled_AE
) O
and O
stroke B-OSE_Labeled_AE
, O
which O
can O
be O
fatal B-NonOSE_AE
. O

Based O
on O
available O
data O
, O
it O
is O
unclear O
that O
the O
risk O
for O
CV B-NonOSE_AE
thrombotic I-NonOSE_AE
events I-NonOSE_AE
is O
similar O
for O
all O
NSAIDs O
. O

The O
relative O
increase O
in O
serious O
CV B-NonOSE_AE
thrombotic I-NonOSE_AE
events I-NonOSE_AE
over O
baseline O
conferred O
by O
NSAID O
use O
appears O
to O
be O
similar O
in O
those O
with O
and O
without O
known O
CV B-Not_AE_Candidate
disease I-Not_AE_Candidate
or O
risk O
factors O
for O
CV B-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

However O
, O
patients O
with O
known O
CV B-Not_AE_Candidate
disease I-Not_AE_Candidate
or O
risk O
factors O
had O
a O
higher O
absolute O
incidence O
of O
excess O
serious O
CV B-NonOSE_AE
thrombotic I-NonOSE_AE
events I-NonOSE_AE
, O
due O
to O
their O
increased O
baseline O
rate O
. O

Some O
observational O
studies O
found O
that O
this O
increased O
risk O
of O
serious O
CV B-OSE_Labeled_AE
thrombotic I-OSE_Labeled_AE
events I-OSE_Labeled_AE
began O
as O
early O
as O
the O
first O
weeks O
of O
treatment O
. O

The O
increase O
in O
CV B-NonOSE_AE
thrombotic I-NonOSE_AE
risk I-NonOSE_AE
has O
been O
observed O
most O
consistently O
at O
higher O
doses O
. O

In O
the O
APC O
( O
Adenoma B-Not_AE_Candidate
Prevention O
with O
Celecoxib O
) O
trial O
, O
the O
hazard O
ratio O
for O
the O
composite O
endpoint O
of O
cardiovascular B-OSE_Labeled_AE
death I-OSE_Labeled_AE
, O
MI B-OSE_Labeled_AE
, O
or O
stroke B-OSE_Labeled_AE
was O
3.4 O
( O
95 O
% O
CI O
1.4 O
- O
8.5 O
) O
for O
CELEBREX O
400 O
mg O
twice O
daily O
and O
2.8 O
( O
95 O
% O
CI O
1.1 O
- O
7.2 O
) O
with O
CELEBREX O
200 O
mg O
twice O
daily O
compared O
to O
placebo O
. O

Cumulative O
rates O
for O
this O
composite O
endpoint O
over O
3 O
years O
were O
3.0 O
% O
( O
20/671 O
subjects O
) O
and O
2.5 O
% O
( O
17/685 O
subjects O
) O
, O
respectively O
, O
compared O
to O
0.9 O
% O
( O
6/679 O
subjects O
) O
with O
placebo O
treatment O
. O

The O
increases O
in O
both O
celecoxib O
dose O
groups O
versus O
placebo-treated O
patients O
were O
mainly O
due O
to O
an O
increased O
incidence O
of O
myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
[ O
see O
Clinical O
Studies O
( O
14.6 O
) O
] O
. O

To O
minimize O
the O
potential O
risk O
for O
an O
adverse B-NonOSE_AE
CV I-NonOSE_AE
event I-NonOSE_AE
in O
NSAID-treated O
patients O
, O
use O
the O
lowest O
effective O
dose O
for O
the O
shortest O
duration O
possible O
. O

Physicians O
and O
patients O
should O
remain O
alert O
for O
the O
development O
of O
such O
events O
, O
throughout O
the O
entire O
treatment O
course O
, O
even O
in O
the O
absence O
of O
previous O
CV B-NonOSE_AE
symptoms I-NonOSE_AE
. O

Patients O
should O
be O
informed O
about O
the O
symptoms O
of O
serious O
CV B-NonOSE_AE
events I-NonOSE_AE
and O
the O
steps O
to O
take O
if O
they O
occur O
. O

There O
is O
no O
consistent O
evidence O
that O
concurrent O
use O
of O
aspirin O
mitigates O
the O
increased O
risk O
of O
serious O
CV B-NonOSE_AE
thrombotic I-NonOSE_AE
events I-NonOSE_AE
associated O
with O
NSAID O
use O
. O

The O
concurrent O
use O
of O
aspirin O
and O
an O
NSAID O
, O
such O
as O
celecoxib O
, O
increases O
the O
risk O
of O
serious O
gastrointestinal B-NonOSE_AE
( I-NonOSE_AE
GI I-NonOSE_AE
) I-NonOSE_AE
events I-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

Status O
Post O
Coronary O
Artery O
Bypass O
Graft O
( O
CABG O
) O
Surgery O
Two O
large O
, O
controlled O
clinical O
trials O
of O
a O
COX-2 O
selective O
NSAID O
for O
the O
treatment O
of O
pain B-Not_AE_Candidate
in O
the O
first O
10-14 O
days O
following O
CABG O
surgery O
found O
an O
increased O
incidence O
of O
myocardial B-NonOSE_AE
infarction I-NonOSE_AE
and O
stroke B-NonOSE_AE
. O

NSAIDs O
are O
contraindicated O
in O
the O
setting O
of O
CABG O
[ O
see O
Contraindications O
( O
4 O
) O
] O
. O

Post-MI O
Patients O
Observational O
studies O
conducted O
in O
the O
Danish O
National O
Registry O
have O
demonstrated O
that O
patients O
treated O
with O
NSAIDs O
in O
the O
post- O
MI B-Not_AE_Candidate
period O
were O
at O
increased O
risk O
of O
reinfarction B-OSE_Labeled_AE
, O
CV B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
death I-OSE_Labeled_AE
, O
and O
all-cause O
mortality B-NonOSE_AE
beginning O
in O
the O
first O
week O
of O
treatment O
. O

In O
this O
same O
cohort O
, O
the O
incidence O
of O
death B-NonOSE_AE
in O
the O
first O
year O
post- O
MI B-Not_AE_Candidate
was O
20 O
per O
100 O
person O
years O
in O
NSAID-treated O
patients O
compared O
to O
12 O
per O
100 O
person O
years O
in O
non-NSAID O
exposed O
patients O
. O

Although O
the O
absolute O
rate O
of O
death B-NonOSE_AE
declined O
somewhat O
after O
the O
first O
year O
post- O
MI B-Not_AE_Candidate
, O
the O
increased O
relative O
risk O
of O
death B-NonOSE_AE
in O
NSAID O
users O
persisted O
over O
at O
least O
the O
next O
four O
years O
of O
follow-up O
. O

Avoid O
the O
use O
of O
Celebrex O
in O
patients O
with O
a O
recent O
MI B-Not_AE_Candidate
unless O
the O
benefits O
are O
expected O
to O
outweigh O
the O
risk O
of O
recurrent O
CV B-NonOSE_AE
thrombotic I-NonOSE_AE
events I-NonOSE_AE
. O

If O
Celebrex O
is O
used O
in O
patients O
with O
a O
recent O
MI B-Not_AE_Candidate
, O
monitor O
patients O
for O
signs O
of O
cardiac B-NonOSE_AE
ischemia I-NonOSE_AE
. O

5.2 O
Gastrointestinal O
Bleeding O
, O
Ulceration O
, O
and O
Perforation O
NSAIDs O
, O
including O
celecoxib O
cause O
serious O
gastrointestinal B-OSE_Labeled_AE
( I-OSE_Labeled_AE
GI I-OSE_Labeled_AE
) I-OSE_Labeled_AE
adverse I-OSE_Labeled_AE
events I-OSE_Labeled_AE
including O
inflammation B-OSE_Labeled_AE
, O
bleeding B-OSE_Labeled_AE
, O
ulceration B-OSE_Labeled_AE
, O
and O
perforation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
the I-OSE_Labeled_AE
esophagus O
, O
stomach O
, O
small I-OSE_Labeled_AE
intestine I-OSE_Labeled_AE
, O
or O
large O
intestine O
, O
which O
can O
be O
fatal B-NonOSE_AE
. O

These O
serious O
adverse O
events O
can O
occur O
at O
any O
time O
, O
with O
or O
without O
warning O
symptoms O
, O
in O
patients O
treated O
with O
CELEBREX O
. O

Only O
one O
in O
five O
patients O
who O
develop O
a O
serious O
upper B-NonOSE_AE
GI I-NonOSE_AE
adverse I-NonOSE_AE
event I-NonOSE_AE
on O
NSAID O
therapy O
is O
symptomatic O
. O

Upper B-OSE_Labeled_AE
GI I-OSE_Labeled_AE
ulcers I-OSE_Labeled_AE
, O
gross O
bleeding O
, O
or O
perforation O
caused O
by O
NSAIDs O
occurred O
in O
approximately O
1 O
% O
of O
patients O
treated O
for O
3-6 O
months O
, O
and O
in O
about O
2 O
% O
-4 O
% O
of O
patients O
treated O
for O
one O
year O
. O

However O
, O
even O
short-term O
NSAID O
therapy O
is O
not O
without O
risk O
. O

Risk O
Factors O
for O
GI O
Bleeding O
, O
Ulceration O
, O
and O
Perforation O
Patients O
with O
a O
prior O
history O
of O
peptic B-Not_AE_Candidate
ulcer I-Not_AE_Candidate
disease I-Not_AE_Candidate
and/or O
GI B-Not_AE_Candidate
bleeding I-Not_AE_Candidate
who O
used O
NSAIDs O
had O
a O
greater O
than O
10-fold O
increased O
risk O
for O
developing O
a O
GI B-OSE_Labeled_AE
bleed I-OSE_Labeled_AE
compared O
to O
patients O
without O
these O
risk O
factors O
. O

Other O
factors O
that O
increase O
the O
risk O
of O
GI B-NonOSE_AE
bleeding I-NonOSE_AE
in O
patients O
treated O
with O
NSAIDs O
include O
longer O
duration O
of O
NSAID O
therapy O
; O
concomitant O
use O
of O
oral O
corticosteroids O
, O
aspirin O
, O
anticoagulants O
; O
or O
selective O
serotonin O
reuptake O
inhibitors O
( O
SSRIs O
) O
; O
smoking O
; O
use O
of O
alcohol O
; O
older O
age O
; O
and O
poor O
general O
health O
status O
. O

Most O
postmarketing O
reports O
of O
fatal B-NonOSE_AE
GI B-OSE_Labeled_AE
events I-OSE_Labeled_AE
occurred O
in O
elderly O
or O
debilitated O
patients O
. O

Additionally O
, O
patients O
with O
advanced O
liver B-Not_AE_Candidate
disease I-Not_AE_Candidate
and/or O
coagulopathy B-Not_AE_Candidate
are O
at O
increased O
risk O
for O
GI B-NonOSE_AE
bleeding I-NonOSE_AE
. O

Complicated O
and O
symptomatic O
ulcer B-OSE_Labeled_AE
rates O
were O
0.78 O
% O
at O
nine O
months O
for O
all O
patients O
in O
the O
CLASS O
trial O
, O
and O
2.19 O
% O
for O
the O
subgroup O
on O
low-dose O
ASA O
. O

Patients O
65 O
years O
of O
age O
and O
older O
had O
an O
incidence O
of O
1.40 O
% O
at O
nine O
months O
, O
3.06 O
% O
when O
also O
taking O
ASA O
[ O
see O
Clinical O
Studies O
( O
14.6 O
) O
] O
. O

Strategies O
to O
Minimize O
the O
GI O
Risks O
in O
NSAID-treated O
patients O
: O
* O
Use O
the O
lowest O
effective O
dosage O
for O
the O
shortest O
possible O
duration O
. O

* O
Avoid O
administration O
of O
more O
than O
one O
NSAID O
at O
a O
time O
. O

* O
Avoid O
use O
in O
patients O
at O
higher O
risk O
unless O
benefits O
are O
expected O
to O
outweigh O
the O
increased O
risk O
of O
bleeding B-NonOSE_AE
. O

For O
such O
patients O
, O
as O
well O
as O
those O
with O
active O
GI B-Not_AE_Candidate
bleeding I-Not_AE_Candidate
, O
consider O
alternate O
therapies O
other O
than O
NSAIDs O
. O

* O
Remain O
alert O
for O
signs O
and O
symptoms O
of O
GI B-NonOSE_AE
ulceration I-NonOSE_AE
and O
bleeding O
during O
NSAID O
therapy O
. O

* O
If O
a O
serious O
GI B-NonOSE_AE
adverse I-NonOSE_AE
event I-NonOSE_AE
is O
suspected O
, O
promptly O
initiate O
evaluation O
and O
treatment O
, O
and O
discontinue O
CELEBREX O
until O
a O
serious O
GI B-NonOSE_AE
adverse I-NonOSE_AE
event I-NonOSE_AE
is O
ruled O
out O
. O

* O
In O
the O
setting O
of O
concomitant O
use O
of O
low-dose O
aspirin O
for O
cardiac O
prophylaxis O
, O
monitor O
patients O
more O
closely O
for O
evidence O
of O
GI B-NonOSE_AE
bleeding I-NonOSE_AE
[ O
see O
Drug O
Interactions O
( O
7 O
) O
] O
. O

5.3 O
Hepatotoxicity B-OSE_Labeled_AE
Elevations B-OSE_Labeled_AE
of I-OSE_Labeled_AE
ALT O
or O
AST I-OSE_Labeled_AE
( O
three O
or O
more O
times O
the O
upper O
limit O
of O
normal O
[ O
ULN O
] O
) O
have O
been O
reported O
in O
approximately O
1 O
% O
of O
NSAID-treated O
patients O
in O
clinical O
trials O
. O

In O
addition O
, O
rare O
, O
sometimes O
fatal B-NonOSE_AE
, O
cases O
of O
severe O
hepatic B-OSE_Labeled_AE
injury I-OSE_Labeled_AE
, O
including O
fulminant B-OSE_Labeled_AE
hepatitis I-OSE_Labeled_AE
, O
liver B-OSE_Labeled_AE
necrosis I-OSE_Labeled_AE
, O
and O
hepatic B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
have O
been O
reported O
. O

Elevations B-OSE_Labeled_AE
of I-OSE_Labeled_AE
ALT I-OSE_Labeled_AE
or O
AST O
( O
less O
than O
three O
times O
ULN O
) O
may O
occur O
in O
up O
to O
15 O
% O
of O
patients O
treated O
with O
NSAIDs O
including O
celecoxib O
. O

In O
controlled O
clinical O
trials O
of O
CELEBREX O
, O
the O
incidence O
of O
borderline O
elevations B-OSE_Labeled_AE
( O
greater O
than O
or O
equal O
to O
1.2 O
times O
and O
less O
than O
3 O
times O
the O
upper O
limit O
of I-OSE_Labeled_AE
normal O
) O
of O
liver I-OSE_Labeled_AE
associated I-OSE_Labeled_AE
enzymes I-OSE_Labeled_AE
was O
6 O
% O
for O
CELEBREX O
and O
5 O
% O
for O
placebo O
, O
and O
approximately O
0.2 O
% O
of O
patients O
taking O
CELEBREX O
and O
0.3 O
% O
of O
patients O
taking O
placebo O
had O
notable O
elevations B-NonOSE_AE
of O
ALT O
and O
AST I-NonOSE_AE
. O

Inform O
patients O
of O
the O
warning O
signs O
and O
symptoms O
of O
hepatotoxicity B-NonOSE_AE
( O
e.g. O
, O
nausea B-NonOSE_AE
, O
fatigue B-NonOSE_AE
, O
lethargy B-NonOSE_AE
, O
diarrhea B-NonOSE_AE
, O
pruritus B-NonOSE_AE
, O
jaundice B-NonOSE_AE
, O
right B-NonOSE_AE
upper I-NonOSE_AE
quadrant I-NonOSE_AE
tenderness I-NonOSE_AE
, O
and O
" B-NonOSE_AE
flu I-NonOSE_AE
- I-NonOSE_AE
like I-NonOSE_AE
" I-NonOSE_AE
symptoms I-NonOSE_AE
) O
. O

If O
clinical O
signs O
and O
symptoms O
consistent O
with O
liver B-NonOSE_AE
disease I-NonOSE_AE
develop O
, O
or O
if O
systemic O
manifestations O
occur O
( O
e.g. O
, O
eosinophilia B-NonOSE_AE
, O
rash B-NonOSE_AE
, O
etc O
. O

) O
, O
discontinue O
CELEBREX O
immediately O
, O
and O
perform O
a O
clinical O
evaluation O
of O
the O
patient O
. O

5.4 O
Hypertension O
NSAIDs O
, O
including O
CELEBREX O
can O
lead O
to O
new O
onset O
of O
hypertension B-OSE_Labeled_AE
or O
worsening B-OSE_Labeled_AE
of I-OSE_Labeled_AE
preexisting I-OSE_Labeled_AE
hypertension I-OSE_Labeled_AE
, O
either O
of O
which O
may O
contribute O
to O
the O
increased O
incidence O
of O
CV B-NonOSE_AE
events I-NonOSE_AE
. O

Patients O
taking O
angiotensin O
converting O
enzyme O
( O
ACE O
) O
inhibitors O
, O
thiazide O
diuretics O
or O
loop O
diuretics O
may O
have O
impaired O
response O
to O
these O
therapies O
when O
taking O
NSAIDs O
[ O
see O
Drug O
Interactions O
( O
7 O
) O
] O
. O

The O
rates O
of O
hypertension B-OSE_Labeled_AE
from O
the O
CLASS O
trial O
in O
the O
CELEBREX O
, O
ibuprofen O
and O
diclofenac-treated O
patients O
were O
2.4 O
% O
, O
4.2 O
% O
and O
2.5 O
% O
, O
respectively O
[ O
see O
Clinical O
Studies O
( O
14.6 O
) O
] O
. O

Monitor O
blood O
pressure O
( O
BP O
) O
during O
the O
initiation O
of O
NSAID O
treatment O
and O
throughout O
the O
course O
of O
therapy O
. O

5.5 O
Heart O
Failure O
and O
Edema O
The O
Coxib O
and O
traditional O
NSAID O
Trialists O
' O
Collaboration O
meta-analysis O
of O
randomized O
controlled O
trials O
demonstrated O
an O
approximately O
two-fold O
increase O
in O
hospitalizations O
for O
heart B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
in O
COX-2 O
selective-treated O
patients O
and O
nonselective O
NSAID-treated O
patients O
compared O
to O
placebo-treated O
patients O
. O

In O
a O
Danish O
National O
Registry O
study O
of O
patients O
with O
heart B-Not_AE_Candidate
failure I-Not_AE_Candidate
, O
NSAID O
use O
increased O
the O
risk O
of O
MI B-OSE_Labeled_AE
, O
hospitalization O
for O
heart B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
and O
death B-NonOSE_AE
. O

Additionally O
, O
fluid B-OSE_Labeled_AE
retention I-OSE_Labeled_AE
and O
edema B-OSE_Labeled_AE
have O
been O
observed O
in O
some O
patients O
treated O
with O
NSAIDs O
. O

Use O
of O
celecoxib O
may O
blunt O
the O
CV B-NonOSE_AE
effects I-NonOSE_AE
of O
several O
therapeutic O
agents O
used O
to O
treat O
these O
medical O
conditions O
( O
e.g. O
, O
diuretics O
, O
ACE O
inhibitors O
, O
or O
angiotensin O
receptor O
blockers O
[ O
ARBs O
] O
) O
[ O
see O
Drug O
Interactions O
( O
7 O
) O
] O
. O

In O
the O
CLASS O
study O
[ O
see O
Clinical O
Studies O
( O
14.6 O
) O
] O
, O
the O
Kaplan-Meier O
cumulative O
rates O
at O
9 O
months O
of O
peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
in O
patients O
on O
CELEBREX O
400 O
mg O
twice O
daily O
( O
4-fold O
and O
2-fold O
the O
recommended O
OA B-Not_AE_Candidate
and O
RA B-Not_AE_Candidate
doses O
, O
respectively O
) O
, O
ibuprofen O
800 O
mg O
three O
times O
daily O
and O
diclofenac O
75 O
mg O
twice O
daily O
were O
4.5 O
% O
, O
6.9 O
% O
and O
4.7 O
% O
, O
respectively O
. O

Avoid O
the O
use O
of O
CELEBREX O
in O
patients O
with O
severe O
heart B-Not_AE_Candidate
failure I-Not_AE_Candidate
unless O
the O
benefits O
are O
expected O
to O
outweigh O
the O
risk O
of O
worsening B-NonOSE_AE
heart I-NonOSE_AE
failure I-NonOSE_AE
. O

If O
CELEBREX O
is O
used O
in O
patients O
with O
severe O
heart B-Not_AE_Candidate
failure I-Not_AE_Candidate
, O
monitor O
patients O
for O
signs O
of O
worsening B-NonOSE_AE
heart I-NonOSE_AE
failure I-NonOSE_AE
. O

5.6 O
Renal O
Toxicity O
and O
Hyperkalemia O
Renal O
Toxicity O
Long-term O
administration O
of O
NSAIDs O
has O
resulted O
in O
renal B-OSE_Labeled_AE
papillary I-OSE_Labeled_AE
necrosis I-OSE_Labeled_AE
and O
other O
renal B-OSE_Labeled_AE
injury I-OSE_Labeled_AE
. O

Renal B-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
has O
also O
been O
seen O
in O
patients O
in O
whom O
renal O
prostaglandins O
have O
a O
compensatory O
role O
in O
the O
maintenance O
of O
renal O
perfusion O
. O

In O
these O
patients O
, O
administration O
of O
an O
NSAID O
may O
cause O
a O
dose-dependent O
reduction B-NonOSE_AE
in I-NonOSE_AE
prostaglandin O
formation O
and O
, O
secondarily O
, O
in O
renal I-NonOSE_AE
blood I-NonOSE_AE
flow I-NonOSE_AE
, O
which O
may O
precipitate O
overt O
renal B-NonOSE_AE
decompensation I-NonOSE_AE
. O

Patients O
at O
greatest O
risk O
of O
this O
reaction O
are O
those O
with O
impaired B-Not_AE_Candidate
renal I-Not_AE_Candidate
function I-Not_AE_Candidate
, O
dehydration B-Not_AE_Candidate
, O
hypovolemia B-Not_AE_Candidate
, O
heart B-Not_AE_Candidate
failure I-Not_AE_Candidate
, O
liver B-Not_AE_Candidate
dysfunction I-Not_AE_Candidate
, O
those O
taking O
diuretics O
, O
ACE-inhibitors O
or O
the O
ARBs O
, O
and O
the O
elderly O
. O

Discontinuation O
of O
NSAID O
therapy O
is O
usually O
followed O
by O
recovery O
to O
the O
pretreatment O
state O
. O

No O
information O
is O
available O
from O
controlled O
clinical O
studies O
regarding O
the O
use O
of O
CELEBREX O
in O
patients O
with O
advanced O
renal B-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

The O
renal B-NonOSE_AE
effects I-NonOSE_AE
of O
CELEBREX O
may O
hasten O
the O
progression B-OSE_Labeled_AE
of I-OSE_Labeled_AE
renal I-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
in O
patients O
with O
preexisting O
renal B-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

Correct O
volume O
status O
in O
dehydrated B-Not_AE_Candidate
or O
hypovolemic B-Not_AE_Candidate
patients O
prior O
to O
initiating O
CELEBREX O
. O

Monitor O
renal O
function O
in O
patients O
with O
renal B-Not_AE_Candidate
or O
hepatic O
impairment I-Not_AE_Candidate
, O
heart B-Not_AE_Candidate
failure I-Not_AE_Candidate
, O
dehydration B-Not_AE_Candidate
, O
or O
hypovolemia B-Not_AE_Candidate
during O
use O
of O
CELEBREX O
[ O
see O
Drug O
Interactions O
( O
7 O
) O
] O
. O

Avoid O
the O
use O
of O
CELEBREX O
in O
patients O
with O
advanced O
renal B-Not_AE_Candidate
disease I-Not_AE_Candidate
unless O
the O
benefits O
are O
expected O
to O
outweigh O
the O
risk O
of O
worsening B-NonOSE_AE
renal I-NonOSE_AE
function I-NonOSE_AE
. O

If O
CELEBREX O
is O
used O
in O
patients O
with O
advanced O
renal B-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
monitor O
patients O
for O
signs O
of O
worsening B-NonOSE_AE
renal I-NonOSE_AE
function I-NonOSE_AE
. O

Hyperkalemia O
Increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
potassium I-OSE_Labeled_AE
concentration I-OSE_Labeled_AE
, O
including O
hyperkalemia B-OSE_Labeled_AE
, O
have O
been O
reported O
with O
use O
of O
NSAIDs O
, O
even O
in O
some O
patients O
without O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
. O

In O
patients O
with O
normal O
renal O
function O
, O
these O
effects O
have O
been O
attributed O
to O
a O
hyporeninemic B-Not_AE_Candidate
- I-Not_AE_Candidate
hypoadosteronism I-Not_AE_Candidate
state I-Not_AE_Candidate
. O

5.7 O
Anaphylactic O
Reactions O
Celecoxib O
has O
been O
associated O
with O
anaphylactic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
in O
patients O
with O
and O
without O
known O
hypersensitivity B-Not_AE_Candidate
to I-Not_AE_Candidate
celecoxib I-Not_AE_Candidate
and O
in O
patients O
with O
aspirin B-Not_AE_Candidate
sensitive I-Not_AE_Candidate
asthma I-Not_AE_Candidate
. O

Celebrex O
is O
a O
sulfonamide O
and O
both O
NSAIDs O
and O
sulfonamides O
may O
cause O
allergic B-OSE_Labeled_AE
type I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
including O
anaphylactic B-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
and O
life-threatening O
or O
less O
severe O
asthmatic B-OSE_Labeled_AE
episodes I-OSE_Labeled_AE
in O
certain O
susceptible O
people O
[ O
see O
Contraindications O
( O
4 O
) O
and O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
. O

Seek O
emergency O
help O
if O
any O
anaphylactic B-NonOSE_AE
reaction I-NonOSE_AE
occurs O
. O

5.8 O
Exacerbation O
of O
Asthma O
Related O
to O
Aspirin O
Sensitivity O
A O
subpopulation O
of O
patients O
with O
asthma B-Not_AE_Candidate
may O
have O
aspirin B-Not_AE_Candidate
- I-Not_AE_Candidate
sensitive I-Not_AE_Candidate
asthma I-Not_AE_Candidate
which O
may O
include O
chronic O
rhinosinusitis B-Not_AE_Candidate
complicated O
by O
nasal B-Not_AE_Candidate
polyps I-Not_AE_Candidate
; O
severe O
, O
potentially O
fatal B-NonOSE_AE
bronchospasm B-Not_AE_Candidate
; O
and/or O
intolerance B-Not_AE_Candidate
to I-Not_AE_Candidate
aspirin I-Not_AE_Candidate
and O
other O
NSAIDs O
. O

Because O
cross B-Not_AE_Candidate
- I-Not_AE_Candidate
reactivity I-Not_AE_Candidate
between O
aspirin O
and O
other O
NSAIDs O
has O
been O
reported O
in O
such O
aspirin-sensitive O
patients O
, O
CELEBREX O
is O
contraindicated O
in O
patients O
with O
this O
form O
of O
aspirin O
sensitivity O
[ O
see O
Contraindications O
( O
4 O
) O
] O
. O

When O
CELEBREX O
is O
used O
in O
patients O
with O
preexisting O
asthma B-Not_AE_Candidate
( O
without O
known O
aspirin B-NonOSE_AE
sensitivity I-NonOSE_AE
) O
, O
monitor O
patients O
for O
changes O
in O
the O
signs O
and O
symptoms O
of O
asthma B-NonOSE_AE
. O

5.9 O
Serious O
Skin O
Reactions O
Serious O
skin B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
have O
occurred O
following O
treatment O
with O
Celebrex O
, O
including O
erythema B-OSE_Labeled_AE
multiforme I-OSE_Labeled_AE
, O
exfoliative B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
, O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
( I-OSE_Labeled_AE
SJS I-OSE_Labeled_AE
) O
, O
toxic B-OSE_Labeled_AE
epidermal I-OSE_Labeled_AE
necrolysis I-OSE_Labeled_AE
( I-OSE_Labeled_AE
TEN I-OSE_Labeled_AE
) O
, O
drug B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
with I-OSE_Labeled_AE
eosinophilia I-OSE_Labeled_AE
and I-OSE_Labeled_AE
systemic I-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
( I-OSE_Labeled_AE
DRESS I-OSE_Labeled_AE
) O
, O
and O
acute B-OSE_Labeled_AE
generalized I-OSE_Labeled_AE
exanthematous I-OSE_Labeled_AE
pustulosis I-OSE_Labeled_AE
( I-OSE_Labeled_AE
AGEP I-OSE_Labeled_AE
) O
. O

These O
serious O
events O
may O
occur O
without O
warning O
and O
can O
be O
fatal B-NonOSE_AE
. O

Inform O
patients O
about O
the O
signs O
and O
symptoms O
of O
serious O
skin B-NonOSE_AE
reactions I-NonOSE_AE
, O
and O
to O
discontinue O
the O
use O
of O
CELEBREX O
at O
the O
first O
appearance O
of O
skin B-NonOSE_AE
rash I-NonOSE_AE
or O
any O
other O
sign O
of O
hypersensitivity B-NonOSE_AE
. O

CELEBREX O
is O
contraindicated O
in O
patients O
with O
previous O
serious O
skin B-Not_AE_Candidate
reactions I-Not_AE_Candidate
to I-Not_AE_Candidate
NSAIDs I-Not_AE_Candidate
[ O
see O
Contraindications O
( O
4 O
) O
] O
. O

5.10 O
Premature O
Closure O
of O
Fetal O
Ductus O
Arteriosus O
Celecoxib O
may O
cause O
premature B-OSE_Labeled_AE
closure I-OSE_Labeled_AE
of I-OSE_Labeled_AE
the I-OSE_Labeled_AE
ductus I-OSE_Labeled_AE
arteriosus I-OSE_Labeled_AE
. O

Avoid O
use O
of O
NSAIDs O
, O
including O
CELEBREX O
, O
in O
pregnant B-Not_AE_Candidate
women O
starting O
at O
30 O
weeks O
of O
gestation O
( O
third O
trimester O
) O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.1 O
) O
] O
. O

5.11 O
Hematological B-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
Anemia B-OSE_Labeled_AE
has O
occurred O
in O
NSAID-treated O
patients O
. O

This O
may O
be O
due O
to O
occult O
or O
gross O
blood B-Not_AE_Candidate
loss I-Not_AE_Candidate
, O
fluid B-Not_AE_Candidate
retention I-Not_AE_Candidate
, O
or O
an O
incompletely O
described O
effect B-Not_AE_Candidate
on I-Not_AE_Candidate
erythropoiesis I-Not_AE_Candidate
. O

If O
a O
patient O
treated O
with O
CELEBREX O
has O
any O
signs O
or O
symptoms O
of O
anemia B-NonOSE_AE
, O
monitor O
hemoglobin O
or O
hematocrit O
. O

In O
controlled O
clinical O
trials O
the O
incidence O
of O
anemia B-OSE_Labeled_AE
was O
0.6 O
% O
with O
CELEBREX O
and O
0.4 O
% O
with O
placebo O
. O

Patients O
on O
long-term O
treatment O
with O
CELEBREX O
should O
have O
their O
hemoglobin O
or O
hematocrit O
checked O
if O
they O
exhibit O
any O
signs O
or O
symptoms O
of O
anemia B-NonOSE_AE
or O
blood B-NonOSE_AE
loss I-NonOSE_AE
. O

NSAIDs O
, O
including O
CELEBREX O
, O
may O
increase O
the O
risk O
of O
bleeding B-OSE_Labeled_AE
events O
. O

Co-morbid O
conditions O
such O
as O
coagulation B-Not_AE_Candidate
disorders I-Not_AE_Candidate
or O
concomitant O
use O
of O
warfarin O
, O
other O
anticoagulants O
, O
antiplatelet O
agents O
( O
e.g. O
, O
aspirin O
) O
, O
serotonin O
reuptake O
inhibitors O
( O
SSRIs O
) O
and O
serotonin O
norepinephrine O
reuptake O
inhibitors O
( O
SNRIs O
) O
may O
increase O
this O
risk O
. O

Monitor O
these O
patients O
for O
signs O
of O
bleeding B-NonOSE_AE
[ O
see O
Drug O
Interactions O
( O
7 O
) O
] O
. O

5.12 O
Masking O
of O
Inflammation O
and O
Fever O
The O
pharmacological O
activity O
of O
CELEBREX O
in O
reducing B-NonOSE_AE
inflammation I-NonOSE_AE
, O
and O
possibly O
fever O
, O
may O
diminish O
the O
utility O
of O
diagnostic O
signs O
in O
detecting O
infections B-NonOSE_AE
. O

5.13 O
Laboratory O
Monitoring O
Because O
serious O
GI B-NonOSE_AE
bleeding I-NonOSE_AE
, O
hepatotoxicity B-NonOSE_AE
, O
and O
renal B-NonOSE_AE
injury I-NonOSE_AE
can O
occur O
without O
warning O
symptoms O
or O
signs O
, O
consider O
monitoring O
patients O
on O
long-term O
NSAID O
treatment O
with O
a O
CBC O
and O
a O
chemistry O
profile O
periodically O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
, O
5.3 O
, O
5.6 O
) O
] O
. O

In O
controlled O
clinical O
trials O
, O
elevated B-OSE_Labeled_AE
BUN I-OSE_Labeled_AE
occurred O
more O
frequently O
in O
patients O
receiving O
CELEBREX O
compared O
with O
patients O
on O
placebo O
. O

This O
laboratory B-NonOSE_AE
abnormality I-NonOSE_AE
was O
also O
seen O
in O
patients O
who O
received O
comparator O
NSAIDs O
in O
these O
studies O
. O

The O
clinical O
significance O
of O
this O
abnormality O
has O
not O
been O
established O
. O

5.14 O
Disseminated O
Intravascular O
Coagulation O
( O
DIC O
) O
Because O
of O
the O
risk O
of O
disseminated B-OSE_Labeled_AE
intravascular I-OSE_Labeled_AE
coagulation I-OSE_Labeled_AE
with O
use O
of O
CELEBREX O
in O
pediatric O
patients O
with O
systemic O
onset O
JRA B-Not_AE_Candidate
, O
monitor O
patients O
for O
signs O
and O
symptoms O
of O
abnormal B-NonOSE_AE
clotting I-NonOSE_AE
or O
bleeding B-NonOSE_AE
, O
and O
inform O
patients O
and O
their O
caregivers O
to O
report O
symptoms O
as O
soon O
as O
possible O
. O

